InvestorsHub Logo
Followers 6
Posts 1400
Boards Moderated 0
Alias Born 08/24/2014

Re: hschlauch post# 44859

Friday, 06/15/2018 10:17:00 PM

Friday, June 15, 2018 10:17:00 PM

Post# of 48316
Obviously melanoma has been the main focus for Oncosec and PISCES will bring the platform validation with good data that leads to an approved therapy. After that first approval I think it will be game on regarding pipeline expansion. If there is a market worth going after I think Merck will be interested. Merck just bought Viralytics and I believe they will be snatching up Oncosec as well after more validation this year. No more huge acquisitions and wasted billions, smaller innovative tech is where they are building assets now.

Lung cancer is a huge market for Merck so I think they might consider trying a combo study with Oncosec in the future in that tumor type. Oncosec does have lung cancer on their list of tumor targets along with melanoma on their website besides TNBC, RCC, Head and Neck, bladder and gastric. When they unveil the next generation of "go anywhere devices" we may hear more about future plans for lung cancer. Just speculation of course. Would be fantastic if they did go after lung cancer.